Novartis Venture Fund has led a round announced as Ribon Therapeutics came out of stealth, with Celgene, Johnson & Johnson Innovation – JJDC and Takeda Ventures also investing.
Ribon Therapeutics, a US-based biotechnology company developing enzyme families activated under cellular stress conditions, emerged from stealth on Friday with $65m in a series B round led by pharmaceutical firm Novartis.
Novartis led the round through its Novartis Venture Fund, investing alongside fellow pharmaceutical companies Celgene, Johnson & Johnson and Takeda, the latter two through their Johnson & Johnson Innovation – JJDC and Takeda Ventures units respectively.
Spinout-focused investment firm Osage University Partners, Column Group, Deerfield Management, US Venture Partners…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
